Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAIN: Nivolumab vs Nivolumab + Relatlimab Maintenance in EBV-associated Recurrent/Metastatic Nasopharyngeal Carcinoma
KCT0009487Phase 2Not yet recruiting
- Sponsor
- NRG Oncology
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, relatlimab in nasopharyngeal carcinoma (NPC), sponsored by NRG Oncology. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on KCT0009487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009487.